<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058356</url>
  </required_header>
  <id_info>
    <org_study_id>KASID_lacidofil_1</org_study_id>
    <nct_id>NCT01058356</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea</brief_title>
  <official_title>Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea: Prospective, Randomized Double-blind, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmbio Korea Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic-Associated Diarrhea (AAD) is a common complication of antibiotic use. The
      frequency of AAD can be high (26 - 60%) or moderate (13-29%) during hospital outbreaks and is
      relatively infrequent in outpatients. The risk factors for AAD include broad-spectrum
      antibiotics, host factors (age, health status, and gender), hospitalization period and
      exposure to nosocomial pathogens. AAD occurs 2-8 weeks after exposure to antibiotics as a
      result of disrupting normal intestinal microflora. One of the roles of normal intestinal
      microflora is to act as a protective barrier that resists the colonization of intestinal
      pathogens. These patients are susceptible to infection by opportunistic pathogens without
      this protective barrier. Probiotic therapy is suited to AAD and Clostridium difficile
      disease. Probiotics assist in reestablishing the disrupted intestinal microflora, enhancing
      immune responses and clearing pathogens and their toxins from the host. Studies using
      probiotics have been reported for the past twenty-eight years (1977~2005), but the studies
      have been variable in trial designs and types of probiotics, had differing doses and
      durations of treatment, and thus have yielded controversial results. The investigators will
      conduct a multi-center, randomized, placebo-controlled, double-blind trial to assess the
      efficacy of the probiotic Lactobacilli (Lacidofil cap®) for the prevention of AAD in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of AAD</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>AAD defined as: Watery stools more than 3 times per day for at least 2 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Bowel Habit Change (Watery Stools More Than 2 Times Per Day for at Least 2 Days)</measure>
    <time_frame>Up to14 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">214</enrollment>
  <condition>Antibiotics Associated Colitis</condition>
  <condition>Pulmonary Infection</condition>
  <arm_group>
    <arm_group_label>IBD research group in KASID</arm_group_label>
    <description>KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with respiratory tract infection who begin receiving antibiotic therapy (both
        hospitalized patients and out-patients)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18

          -  Patients with respiratory tract infection who are receiving an oral or injection
             antibiotics.

          -  Signed informed consent form prior to inclusion in the study.

          -  Patients who begin receiving antibiotics within 48 hours before enrollment in this
             study.

        Exclusion Criteria:

          -  Diagnosed Clostridium difficile colitis within the last 3 months

          -  Patients with tube feeding, ileostomy or colostomy

          -  Patients with basal diarrheal disease; acute enteritis, chronic diarrhea such as
             inflammatory bowel disease (IBD) etc, radiation enteritis, ischemic colitis and
             diarrhea caused by carcinoids etc.

          -  Patients receiving other probiotics during the last 15 days

          -  Patients treated with immunosuppressant drugs or immune deficiency patients

          -  Patients with radiotherapy and chemotherapy treatment for cancer.

          -  Patients treated with antidiarrheal, antispasmodic or motility agents for other
             diseases.

          -  Pregnant/Lactating women

          -  Patients with gastrointestinal (GI) surgery during the last 3 months.

          -  A history of hypersensitivity to cephalosporins, penicillin or clavulanic acid.

          -  Patients with verified diabetic autonomic neuropathy.

          -  Patients with organ transplants.

          -  Patients with underlying conditions or diseases which, in the opinion of the
             investigator, are unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Ae Jung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KASID IBD Research Group</name>
      <address>
        <city>Seoul</city>
        <zip>135-280</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <results_first_submitted>March 8, 2010</results_first_submitted>
  <results_first_submitted_qc>March 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2010</results_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>NAM, Bong kil/ CEO &amp; President</name_title>
    <organization>Pharmbio Korea</organization>
  </responsible_party>
  <keyword>antibiotics associated colitis</keyword>
  <keyword>lactobacilli</keyword>
  <keyword>probiotics</keyword>
  <keyword>prevention</keyword>
  <keyword>pulmonary infection</keyword>
  <keyword>Prevention of antibiotics associated colitis</keyword>
  <keyword>the role of probiotics for prevention of antibiotics associated colitis</keyword>
  <keyword>the lactobacilli effect for antibiotics associated colitis</keyword>
  <keyword>antibiotic associated colitis on pulmonary infectious disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From September 2008 to November 2009, medical clinic</recruitment_details>
      <pre_assignment_details>Patients who begin receiving antibiotics prior to 48 hours before enrollment in this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lacidofil Capsule Versus Placebo Drug</title>
          <description>Lacidofil capsule: Lactobacillus rhamnosus R0011‧Lactobacillus acidophilus R0052 bacterial culture (2x109), maltodextrin, Mg stearate, ascorbic acid (1 capsule twice a day for 14 days) Placebo drug: maltodextrin, Mg stearate, ascorbic acid
(1 capsule twice a day for 14 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of contraindicated drugs</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lacidofil Capsule Versus Placebo Drug</title>
          <description>Lacidofil capsule: Lactobacillus rhamnosus R0011‧Lactobacillus acidophilus R0052 bacterial culture (2x109), maltodextrin, Mg stearate, ascorbic acid (1 capsule twice a day for 14 days) Placebo drug: maltodextrin, Mg stearate, ascorbic acid
(1 capsule twice a day for 14 days)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of AAD</title>
        <description>AAD defined as: Watery stools more than 3 times per day for at least 2 days.</description>
        <time_frame>Up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lacidofil Capsule Versus Placebo Drug</title>
            <description>Lacidofil capsule: Lactobacillus rhamnosus R0011‧Lactobacillus acidophilus R0052 bacterial culture (2x109), maltodextrin, Mg stearate, ascorbic acid (1 capsule twice a day for 14 days) Placebo drug: maltodextrin, Mg stearate, ascorbic acid
(1 capsule twice a day for 14 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of AAD</title>
          <description>AAD defined as: Watery stools more than 3 times per day for at least 2 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The efficay of the probiotic Lactobacilli (Lacidofil cap®) for the prevention of AAD in adults is not different form the placebo group in multi-center, randomized, placebo-controlled, double-blind trial.
Power calculation:
The assumption of sample size calculation:
difference 18% (8% : 26%) α: 0.05, statistical power: 90%, two sided difference: 18% Compliance: 80%
- Unadjusted sample size (N=200) 180 + 10(%) drop out = 180 + 180/ (1-0.1)2 = 222.2 Total 220 subjects</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>4.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Bowel Habit Change (Watery Stools More Than 2 Times Per Day for at Least 2 Days)</title>
        <time_frame>Up to14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lacidofil Capsule Versus Placebo Drug</title>
            <description>Lacidofil capsule: Lactobacillus rhamnosus R0011‧Lactobacillus acidophilus R0052 bacterial culture (2x109), maltodextrin, Mg stearate, ascorbic acid (1 capsule twice a day for 14 days) Placebo drug: maltodextrin, Mg stearate, ascorbic acid
(1 capsule twice a day for 14 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Bowel Habit Change (Watery Stools More Than 2 Times Per Day for at Least 2 Days)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The efficay of the probiotic Lactobacilli (Lacidofil cap®) for the prevention of AAD in adults is not different form the placebo group in multi-center, randomized, placebo-controlled, double-blind trial.
Power calculation:
The assumption of sample size calculation:
difference 18% (8% : 26%) α: 0.05, statistical power: 90%, two sided difference: 18% Compliance: 80%
- Unadjusted sample size (N=200) 180 + 10(%) drop out = 180 + 180/ (1-0.1)2 = 222.2 Total 220 subjects</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lacidofil Capsule Versus Placebo Drug</title>
          <description>Lacidofil capsule: Lactobacillus rhamnosus R0011‧Lactobacillus acidophilus R0052 bacterial culture (2x109), maltodextrin, Mg stearate, ascorbic acid (1 capsule twice a day for 14 days) Placebo drug: maltodextrin, Mg stearate, ascorbic acid
(1 capsule twice a day for 14 days)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Korea Association for the Study of Intestinal Disease (KASID)</name_or_title>
      <organization>Pharmbio Korea Co., Ltd.</organization>
      <phone>82-2-587-2551</phone>
      <email>pharmbio@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

